FDA approves new manufacturing site for Cumberland's Sancuso; $1M milestone due

CUMBERLAND PHARMACEUTICALS INC

FDA approved Kindeva as new manufacturing and packaging site for Sancuso on Dec. 6, 2022.
Cumberland acquired U.S. rights to Sancuso in Jan. 2022; Kyowa Kirin led the FDA submission.
Cumberland will pay Kyowa Kirin a $1 million milestone payment following the approval.
Sancuso is the first FDA-approved transdermal patch for chemotherapy-induced nausea/vomiting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.